ViroStatics is a privately held small pharmaceutical company dedicated to the discovery and the development of novel compounds for a multifaceted treatment of cancers and viral diseases, focusing on novel, selective, host cell kinase targeted inhibitors.
The Company has developed a robust pipeline of proprietary compounds to distinguish themselves from the competition through their unique kinase selectivity, efficacy and safety profiles.
Consistent with its well defined mechanism of action, ViroStatics’ lead compound has a good toxicity profile while exerting potent activity in preclinical models against most aggressive cancers with high unmet need such as lung cancer, pancreatic cancer, highly malignant lymphoma and acute leukemia.
The Team and Advisors combines scientific, business, legal, and technology expertise, spanning the entire process of drug development from translational science through preclinical and clinical drug development.
ViroStatics has been awarded with H2020 Seal of Excellence and subsequently obtained funding under the Horizon 2020’s SME Instrument Phase 1 Call H2020-SME Inst-2016-2017 in the area of Dedicated Support to Biotechnology.